Jeff Maca

926 total citations
16 papers, 525 citations indexed

About

Jeff Maca is a scholar working on Statistics and Probability, Economics and Econometrics and Management Science and Operations Research. According to data from OpenAlex, Jeff Maca has authored 16 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Statistics and Probability, 6 papers in Economics and Econometrics and 3 papers in Management Science and Operations Research. Recurrent topics in Jeff Maca's work include Statistical Methods in Clinical Trials (13 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Biosimilars and Bioanalytical Methods (3 papers). Jeff Maca is often cited by papers focused on Statistical Methods in Clinical Trials (13 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Biosimilars and Bioanalytical Methods (3 papers). Jeff Maca collaborates with scholars based in United States, Switzerland and United Kingdom. Jeff Maca's co-authors include Michael Krams, Wolfgang Arns, Michael Hall, Federico Oppenheimer, Herwig Holzer, Angelo de Mattos, Hans W. Sollinger, Maurizio Salvadori, Paul Gallo and Vladimir Dragalin and has published in prestigious journals such as Neurology, PEDIATRICS and American Journal of Transplantation.

In The Last Decade

Jeff Maca

14 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeff Maca United States	8	237	203	113	107	84	16	525
Gaohong Dong United States	17	255 1.1×	556 2.7×	83 0.7×	93 0.9×	29 0.3×	52	1.1k
Étienne Dantan France	8	63 0.3×	286 1.4×	24 0.2×	21 0.2×	10 0.1×	27	554
Sarah Goring United States	15	67 0.3×	12 0.1×	9 0.1×	93 0.9×	5 0.1×	37	613
Yuping Dong United States	7	19 0.1×	178 0.9×	18 0.2×	64 0.6×	2 0.0×	11	596
L. Esserman United States	7	207 0.9×	2 0.0×	12 0.1×	106 1.0×	46 0.5×	39	703
Jérémie Gras Belgium	11	13 0.1×	142 0.7×	10 0.1×	6 0.1×	5 0.1×	28	528
Kinjal Sanghavi United States	11	21 0.1×	177 0.9×	33 0.3×	11 0.1×	4 0.0×	24	526
Jules T. Mitchel United States	10	63 0.3×		35 0.3×	71 0.7×	14 0.2×	16	354
Michael D. deB. Edwardes Canada	7	47 0.2×	21 0.1×	4 0.0×	14 0.1×	4 0.0×	16	560
Dankward Kodlin United States	8	52 0.2×	4 0.0×	9 0.1×	22 0.2×	18 0.2×	18	322

Countries citing papers authored by Jeff Maca

Since Specialization

Citations

This map shows the geographic impact of Jeff Maca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Maca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Maca more than expected).

Fields of papers citing papers by Jeff Maca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Maca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Maca. The network helps show where Jeff Maca may publish in the future.

Co-authorship network of co-authors of Jeff Maca

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Maca. A scholar is included among the top collaborators of Jeff Maca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Maca. Jeff Maca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Pozo‐Rosich, Patricia, David Doležil, Koen Paemeleire, et al.. (2024). Early Use of Erenumab vs Nonspecific Oral Migraine Preventives. JAMA Neurology. 81(5). 461–461. 16 indexed citations

Penner, Iris‐Katharina, Gavin Giovannoni, Tanuja Chitnis, et al.. (2022). Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis: Post Hoc Analysis from the EXPAND Study (P5-4.006). Neurology. 98(18_supplement).

Maca, Jeff, et al.. (2018). Enhancing Pediatric Clinical Trial Feasibility Through the Use of Bayesian Statistics. PEDIATRICS. 141(1_MeetingAbstract). 265–265. 1 indexed citations

Maca, Jeff, et al.. (2018). Enhancing Pediatric Clinical Trial Feasibility Through the Use of Bayesian Statistics. 265–265. 1 indexed citations

Jiang, Qi, Christy Chuang‐Stein, Cyrus R. Mehta, et al.. (2017). Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus. Statistics in Biopharmaceutical Research. 9(4). 347–360. 3 indexed citations

He, Weili, Paul Gallo, Jeff Maca, et al.. (2016). Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs. Therapeutic Innovation & Regulatory Science. 51(1). 60–68. 6 indexed citations

Gallo, Paul, Weili He, Lisa A. Kammerman, et al.. (2016). DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs. Therapeutic Innovation & Regulatory Science. 51(1). 77–88. 7 indexed citations

Jiang, Qi, Chunlei Ke, Haijun Ma, et al.. (2015). Evaluation and Review of Strategies to Assess Cardiovascular Risk in Clinical Trials in Patients with Type 2 Diabetes Mellitus. Statistics in Biopharmaceutical Research. 7(4). 253–266. 6 indexed citations

Maca, Jeff, Vladimir Dragalin, & Paul Gallo. (2013). Adaptive Clinical Trials: Overview of Phase III Designs and Challenges. Therapeutic Innovation & Regulatory Science. 48(1). 31–40. 11 indexed citations

10.

Atkinson, Gary, Abdel Douiri, Thomas Jaki, et al.. (2013). Multiplicity: discussion points from the Statisticians in the Pharmaceutical Industry multiplicity expert group. Pharmaceutical Statistics. 12(5). 255–259. 15 indexed citations

11.

Gaydos, Brenda, et al.. (2010). Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clinical Trials. 7(2). 167–173. 44 indexed citations

12.

Gaydos, Brenda, Keaven M. Anderson, Donald A. Berry, et al.. (2009). Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Drug Information Journal. 43(5). 539–556. 63 indexed citations

13.

Maca, Jeff. (2007). A Review of: “Adaptive Design Methods in Clinical Trials, by S.-C. Chow and Mark Chang”. Journal of Biopharmaceutical Statistics. 18(1). 203–205.

14.

Maca, Jeff, et al.. (2006). Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples. Drug Information Journal. 40(4). 463–473. 87 indexed citations

15.

Salvadori, Maurizio, Herwig Holzer, Angelo de Mattos, et al.. (2004). Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant Patients. American Journal of Transplantation. 4(2). 231–236. 243 indexed citations

16.

Maca, Jeff, et al.. (2002). RECONSIDERING SOME ASPECTS OF THE TWO-TRIALS PARADIGM. Journal of Biopharmaceutical Statistics. 12(2). 107–119. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact